AstraZeneca's efzimfotase alfa adult data spark bullish Citi target, but approval remains uncertain

What happened

Data from the Phase III HICKORY trial of efzimfotase alfa in adults with hypophosphatasia were presented at the American Society for Bone and Mineral Research meeting. Citi maintained a Buy rating with a £186 target, citing peak sales potential of $4.4 billion if the therapy secures broad adult approval in the US, nearly double its base case. The drug is an enzyme replacement therapy for a rare inherited bone disorder, and the adult population represents a meaningful expansion opportunity beyond the current pediatric-focused market. AstraZeneca's 20-F already flags auditor scrutiny on probability-of-success and peak-sales assumptions, increasing sensitivity to such trial outcomes. While the data appear clinically encouraging, regulatory approval is not guaranteed, and the $4.4 billion figure is a third-party estimate that hinges on label breadth and market access.

Implication

For current holders, the efzimfotase alfa data add a positive data point but do not resolve the core concerns of mixed pipeline productivity and rich valuation at 28.1x P/E. The bull scenario in the master report already assumes higher approval cadence, so this news is consistent with that but not sufficient to upgrade the rating. Investors should monitor regulatory interactions and label specifics, as broad adult approval would be required to justify the $4.4 billion peak sales estimate. Until then, the stock remains fairly valued, and a pullback toward the attractive entry level near $170 would offer a better risk-adjusted opportunity. Any material deterioration in legal or pipeline setbacks would still de-rate the shares, so position sizing should remain conservative pending clearer evidence.

Thesis delta

The core thesis is unchanged: AZN trades at a premium with limited tolerance for disappointments, and the next 6-12 months will test pipeline net productivity and legal risk. The efzimfotase alfa adult data are a positive but still contingent on regulatory success, and they do not materially shift the probability-weighted outcomes. If broad approval and strong launch execution materialize, it could add to the bull case, but that remains speculative and requires confirmation from company filings and further trial results.